Review: The role of paraoxonase in cardiovascular diseases

Annals of Clinical and Laboratory Science

Volumn 45, Issue 2, 2015, Pages 226-233

  Kowalska, Katarzyna ^a   Socha, Ewelina ^a   Milnerowicz, Halina ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cardiovascular diseases; Lipid profile; Paraoxonase; Polymorphisms of PON1, PON2 and PON3

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME SPECIFICITY; EXON; GENOTYPE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; INTRON; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC;

EID: 84929318054     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. World Health Organisation Raport 2008
2. Mogac M, Wysocki H. Current concepts of the development of atherosclerotic plaque. Cardiovascular Forum 2004;9:41-46. [article in polish]
3. Berek K, Bobinski R. Atherosclerosis- a multifactorial disease. Problemy Pielegniarstwa 2009;17:257-262. [article in polish]
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
5. Kuliszkiewicz-Janus M, Mohamed AS, Abod N. The biology of HDL lipoprotein and its antisclerotic activity. Postepy Hig Med Dosw 2006; 60:307-315.
6. Jonas A, Philips MC. Lipoprotein structure. In: Biochemistry of lipids, lipoproteins and membranes (Vance DE, Vance JE), Elsevier, Amsterdam, 2008; pp 485-504.
7. Skoczynska A. The role of lipids in atherogenesis. Postepy Hig Med Dosw 2005;59:346-357.
8. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010;411:1875-1882.
9. Dembinska-Kiec A, Naskalski JW. Laboratory diagnostics with elements of clinical biochemistry. Wroclaw: Urban & Partner, 2002.
10. NorataGD, Pirillo A, Catapano AL. ModifiedHDL: Biological and physiopathological consequences. Nutrition 2006;16:371-386.
11. Francis GA. The complexity of HDL. Bioch et Bioph Acta 2010;1801:1286-1293.
12. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.
13. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-419.
14. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M: The catalytic histidine dyad of high density lipoprotein associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657-7665.
15. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein - associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000;275:33435-33442.
16. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase - 1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-547.
17. Rochu D, Chabriere E, Masson P. Human paraoxonase: a promising approach for pre- treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47-59.
18. Zielaskowska J, Olszewska-Slonina D. The polymorphism of paraoxonase and its effects in physiological and pathological processes. Adv Clin Exp Med 2006;15:1073-1078.
19. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du NB. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
20. Gaidukov L, Tawfik DS: High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with Apo A-I. Biochemistry 2005;44:11843-11854.
21. Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, Levy E. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011;214:20-36.
22. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-44449.
23. Lu H, Zhu J, Zang Y, Ze Y, Qin J. Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expr Purif 2006;46:92-99.
24. Draganov DI. Human PON3, effects beyond the HDL: clues from human PON3 transgenic mice. Circ Res 2007;100:1104-1105.
25. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119-120:379-388.
26. Berrougui H, Loued S, Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Radic Biol Med 2012;52:1372-1381.
27. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis Supplements 2002;3:49-55.
28. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005;179:17-25.
29. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-1316.
30. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Art Thromb Vasc Biol 2003;23:468-474.
31. Shiner M, Fuhrman B, Aviram M. A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity. Biochem Biophys Res Commun 2006;349:1094-1099.
32. Litvinov D, Mahini H, Garelnabi M. Antioxidant and antiinflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012;4:523-532.
33. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-550.
34. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn. Schmiedebergs Arch Pharmacol 2004;369:78-88.
35. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 2009;130:361-368.
36. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
37. Pérez-Herrera N, May-Pech C, Hernández-Ochoa I, Castro-Mañé J, Rojas-García E, Borja-Aburto VH, Castillo-Burguete T, Quintanilla-Vega B. PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy. Exp Mol Pathol 2008;85:129-134.
38. Lima J, Alexandre P, Leão L, Rodrigues L, Almeida M, Leal D. Paraoxonase Activity Polymorphism Relationships With Lipid Profiles in a Brazilian Population. Epidemiology 2007;18:168.
39. Gamboa R, Zamora J, Rodriguez-Perez JM, Fragoso JM, Cardoso G, Posadas-Romero C, Vargas-Alarcon G. Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp Mol Pathol 2006;80:85-90.
40. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-1342.
41. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-1624.
42. Demirdögen BC, Türkanoglu A, Bek S, Sanisoglu Y, Demirkaya S, Vural O, Arinç E. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008;41:1-9.
43. Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421-431.
44. Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM, Marian AJ. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 2001;154:633-640.
45. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. The Lancet 2004;363:689-695.
46. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pourmotabbed T, Shakiba E, Vaisi-Raygani A, Kiani A, Aminian M, Alibakhshi R, Bartels C. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep 2011;38:5421-5428.
47. Ombres D, Pannitteri G, Montali A, Candelloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M. The Gln-Arg192 Polymorphism Of Human Paraoxonase Gene Is Not Associated With Coronary Artery Disease In Italian Patients. Arterioscler Thromb Vasc Biol 1998;18:1611-1616.
48. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Physiol Res 2005;54:287-293.
49. Garin MCB, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006; 47:515-520.
50. Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino-Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004;94:73-77.
51. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60.